Creative Biolabs has announced the expansion of its advanced single-cell multi-omics and RNA sequencing solutions, a move that could significantly impact biomedical discovery by providing researchers with more comprehensive tools to analyze cellular heterogeneity. The upgraded suite offers end-to-end services ranging from single-cell transcriptome profiling to integrated multimodal and multi-omics workflows, supporting global researchers across oncology, immunology, and neuroscience.
As life science research increasingly transitions from bulk tissue profiling to single-cell resolution, dissecting cellular heterogeneity has become essential for identifying rare cell subpopulations, characterizing complex tumor microenvironments, and tracing cell lineage trajectories. To support these critical pipelines, Creative Biolabs delivers robust, high-throughput single-cell RNA sequencing services that offer high sensitivity and coverage across thousands of individual cells, delivering high-resolution transcriptomic insights from diverse fresh biological specimens.
Addressing the long-standing laboratory challenge of processing complex, fibrous, or biobanked archival samples, the platform also features specialized single-nucleus RNA sequencing (snRNA-seq) capabilities. For tissues where single-cell dissociation is prone to cell damage, dissociation-induced stress responses, or selective loss of fragile cell types—such as human brain, myocardium, or flash-frozen clinical biopsies—Creative Biolabs provides an optimized single-cell nuclei RNA sequencing service. By isolating intact nuclei, this approach bypasses harsh enzymatic dissociation while minimizing dissociation-related artifacts while retaining informative nuclear RNA profiles, dramatically expanding the scope of clinical translational research.
Recognizing that cellular identity is orchestrated across multiple regulatory layers, Creative Biolabs goes beyond single-dimensional analysis by advancing its high-throughput single-cell multi-omics service. This integrated platform allows the simultaneous interrogation of genomic variations, epigenomic landscapes (e.g., chromatin accessibility), cell surface proteomics (CITE-seq), and transcriptomes within identical single cells. By directly linking epigenetic regulation and genomic alterations to gene expression readouts, the service enables researchers to construct multi-dimensional cellular atlases and uncover novel therapeutic targets with unprecedented biological clarity.
"Understanding biology at single-cell and single-nucleus resolution is no longer a luxury—it is fundamental to precision medicine and biomarker discovery," said a senior scientist at Creative Biolabs. "Our goal is to provide researchers with a seamless, modular analytical ecosystem that transforms difficult biological samples into reliable, high-dimensional datasets with rigorous bioinformatics support."
Supported by advanced microfluidics technologies, stringent quality control benchmarks, and tailored bioinformatics pipelines, Creative Biolabs continues to partner with academic and biopharmaceutical research teams worldwide to unravel the complexities of human disease.
The expansion of these services comes at a time when the demand for high-resolution cellular profiling is escalating. For the healthcare and life sciences industry, this means that researchers can now access a more integrated approach to studying diseases at the single-cell level, potentially accelerating the development of targeted therapies and biomarkers. In oncology, for instance, the ability to analyze tumor microenvironments with multi-omics can lead to more precise immunotherapies. In neuroscience, snRNA-seq enables the study of brain tissue that was previously difficult to analyze, opening new avenues for understanding neurodegenerative diseases. Ultimately, these advancements could translate into improved diagnostics and treatments for patients, underscoring the importance of continued innovation in single-cell technologies.
